A world without late-stage cancer

By harnessing advanced data science and proprietary technology that is non-invasive, highly accurate and cost-effective, Ark is improving medical discovery and enabling the assessment of cancer risk before symptoms appear.

Eradicating Late-Stage Cancer Deaths Through Early Detection

  • 1 out of every 4 people will get cancer. It is more likely than not that every one of us will be affected by cancer, whether personally or through a loved one.
  • Early detection can be the difference between life and death. We may not be able to prevent all cancers, but we can intercept cancer in the early stages, when treatment is more effective.
  • A new generation of blood-based screening tests can detect cancer accurately before any symptoms appear. In contrast, traditional blood tests for cancer detect less than 70% of cancers and have a high level of false-positives.

Our solution

We have developed a sensitive, non-invasive and cost-effective miRNA detection technologies to empower physicians and individuals to detect cancer early. With a simple blood test, we can detect cell-free miRNAs secreted by tumor cells, even before clinical symptoms appear.

We are evidence-based

Our products are evidence-based and have been researched using the largest qPCR-based miRNA database derived through 40,000 clinical samples. We partner with global leaders such as Harvard Medical School, J&J Innovation, A*STAR, and NUS to uncover novel cancer biomarkers.

We adhere to rigorous processes

Quality is at the heart of our scientific pursuit. We adhere to internationally recognised quality standards in research, production, and laboratory testing.

We are committed to research

Ark is committed to build a cancer miRNA atlas by characterizing tens of thousands of cancer patients and matched healthy individuals. We are validating our products through Asia’s largest cancer miRNA-related studies with leading medical institutions in China, Japan, Korea, Singapore and other Southeast Asian nations.